Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health, through HHS, is seeking to establish a Center for the Advancement of Substance Use Disorder pharmacotherapeutics through training and preclinical support. The center will train and mentor researchers in formal product development for new SUD pharmacotherapeutics and provide outreach, drug development training and education, and support for preclinical studies through its administrative and technical cores. This is a cooperative agreement with clinical trials not allowed, while human subjects work that is not a clinical trial may be proposed, and the project period can run up to five years. NIH plans to commit $3 million for one award in FY 2027, applications are due September 30, 2026, and submissions must be made electronically through ASSIST or an institutional system-to-system solution; the contact listed is Tam Nguyen at nidagmbemail@nida.nih.gov.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.